The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Selective versus routine use of pegfilgrastim in dose-dense chemotherapy.
 
Alexandra R. Pass
Honoraria - Abbott Laboratories (I); Alfacell (I); GE Healthcare (I); GlaxoSmithKline (I); Myriad Genetics (I); Prometheus (I); Teva (I)
Consulting or Advisory Role - Champions Oncology (I)
Speakers' Bureau - Genentech (I)
Research Funding - 20/20 GeneSystems (I); Belluck and Fox (I); Celera (I); Centers for Disease Control (I); Department of Defense (I); Integrated Diagnostics (I); Mesothelioma Applied Research Foundation (I); National Cancer Institute (I); NIH (I); Simmons Mesothelioma Foundation (I); SomaLogic (I); Source MDx (I); The Lung Cancer Foundation of America (I); The National Heart Lung and Blood Institute (I); Transgenomic (I)
Patents, Royalties, Other Intellectual Property - Fujirebio Diagnostics (I); Rosetta Genomics (I)
 
Caylin Lo
No Relationships to Disclose
 
Jennifer Bishop
No Relationships to Disclose
 
K. M. Steve Lo
No Relationships to Disclose